Intrexon Corporation Target of Unusually Large Options Trading (XON)
Intrexon Corporation (NYSE:XON) saw some unusual options trading activity on Tuesday. Investors acquired 11,979 call options on the stock. This represents an increase of Infinity compared to the typical volume of 0 call options.
Intrexon Corporation (XON) opened at $13.62 on Friday. Intrexon Corporation has a fifty-two week low of $10.26 and a fifty-two week high of $31.85. The company has a current ratio of 2.05, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01.
Several equities research analysts have weighed in on XON shares. Northland Securities set a $30.00 target price on shares of Intrexon Corporation and gave the company a “buy” rating in a research note on Monday, August 7th. Stifel Nicolaus raised their target price on shares of Intrexon Corporation from $39.00 to $57.00 and gave the company a “buy” rating in a research note on Friday, November 10th. Griffin Securities reaffirmed a “buy” rating and issued a $55.00 price target on shares of Intrexon Corporation in a report on Friday, October 6th. Bank of America Corporation decreased their price target on shares of Intrexon Corporation from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, November 10th. Finally, JMP Securities reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Intrexon Corporation in a report on Thursday, October 5th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $38.50.
In other news, Director Robert B. Shapiro bought 2,850 shares of the stock in a transaction on Tuesday, August 22nd. The stock was bought at an average cost of $17.50 per share, for a total transaction of $49,875.00. Following the completion of the purchase, the director now directly owns 43,157 shares in the company, valued at $755,247.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 55.10% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC raised its holdings in shares of Intrexon Corporation by 2,031.7% in the second quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock worth $125,000 after buying an additional 4,937 shares during the last quarter. Federated Investors Inc. PA purchased a new position in shares of Intrexon Corporation in the second quarter worth $172,000. SG Americas Securities LLC purchased a new position in shares of Intrexon Corporation during the third quarter worth $139,000. Principal Financial Group Inc. purchased a new position in shares of Intrexon Corporation during the second quarter worth $212,000. Finally, Advisor Group Inc. raised its holdings in shares of Intrexon Corporation by 61.5% during the second quarter. Advisor Group Inc. now owns 8,797 shares of the biotechnology company’s stock worth $212,000 after purchasing an additional 3,351 shares during the last quarter. 77.28% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/intrexon-corporation-target-of-unusually-large-options-trading-xon/1708712.html.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.